It's ethical to try untested Ebola medicines: UN

Image
AP Madrid
Last Updated : Aug 12 2014 | 6:16 PM IST
The World Health Organisation today declared that it's ethical to use unproven Ebola drugs and vaccines in the outbreak in West Africa provided the right conditions are met.
The statement from the UN health agency came amid a worldwide debate over the medical ethnics surrounding the Ebola outbreak, which it has called an international health emergency.
However, the agency sidestepped the key questions of who should get the limited drugs and how that should be decided. The statement came after the agency held a teleconference with experts yesterday to discuss the issue.
WHO says 1,013 people have died so far in the Ebola outbreak in West Africa and authorities have recorded 1,848 suspected or confirmed cases. The killer virus was detected in Guinea in March and has since spread to Sierra Leone, Liberia and possibly Nigeria.
Two Americans and reportedly a Spanish priest have gotten an experimental Ebola treatment never tested in humans and two more Ebola treatments were said to be on their way to treat two doctors in Liberia. The vast majority of Ebola victims are Africans, and some nations have protested that their citizens are not getting access to the experimental drugs.
The Spanish missionary priest, 75-year-old Miguel Parajes, died today in a Madrid hospital, the hospital and his order said. The hospital would not confirm that he had been treated with the drug, but his order and Spain's Health Ministry said earlier that he would be.
WHO decided it is ethical to use experimental treatments and vaccines in an ongoing outbreak. There is no evidence yet that these experimental drugs can actually help fight Ebola and it is possible they could be harmful. Still, this outbreak has had about a 50 per cent death rate, according to the UN, adding urgency to the search for a treatment.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 12 2014 | 6:16 PM IST

Next Story